Jefferies, Goldman Sachs, Evercore ISI and Guggenheim acted as joint book running managers for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics Faces Internal Control Challenges
- Spyre Therapeutics announces $200M common stock offering
- Spyre Therapeutics price target raised to $65 from $50 at Baird
- Spyre Therapeutics Reports Promising Trial Results for SPY001
- Spyre Therapeutics’ SPY001 shows efficacy, safety in Phase 1 bowel disease trial
